Stress-response kinase-targeting drug candidates
HC-5404 and HC-7366 target PERK and GCN2, respectively; both were completing Phase 1a clinical trials.
Source: LinkedIn company description · Retrieved October 13, 2026
HiberCell is a clinical-stage oncology company advancing agents.
The company focuses on therapeutic modulation of adaptive stress pathways and anti-tumor immunity in relation to tumor metastasis, treatment resistance and cancer relapse.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
HC-5404 and HC-7366 target PERK and GCN2, respectively; both were completing Phase 1a clinical trials.
Source: LinkedIn company description · Retrieved October 13, 2026
Odetiglucan modulates the anti-tumor innate immune response and was in Phase 2 clinical development.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 15, 2026, September 16, 2026, September 18, 2026, September 19, 2026 and September 21, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.